Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chengdu Kangnuoxing Biopharmaceutical Technology
Chengdu, Sichuan, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Keymed/Kangnuoxing has advanced Stapokibart (CM310), an IL-4α monoclonal antibody, to NDA (accepted by NMPA, China), obtaining priority review for multiple indications; the product has shown strong Phase III data for moderate-to-severe atopic dermatitis and chronic rhinosinusitis with nasal polyposis, marking the first domestic biologic for these indications in China.
- Therapeutic areas
- ImmunologyNephrologyInfectious DiseasesHematologyDermatologyPulmonologyOncology
- Modalities
- Monoclonal antibodyAntibodyAntibody-drug conjugatesiRNA-based drugsBiologic
- Industry
- Biotech
02
Partnerships
AstraZeneca (global exclusive license: Stapokibart/CM310)CSPC (China rights for CM310 and CM326)InnoCare (co-development for neurology programs, CD20xCD20 bispecific, CD38 mAb)Lepu Biopharma (CMG901)Mabworks (CM312)Rona Therapeutics (siRNA glomerulonephritis)Timberlyne (license: CD38 monoclonal antibody CM313)Belenos (rights to CM512, CM536, $185M milestone agreement)Ouro Medicines (financing/licensing: CM336)Prolium (license: CD20xCD20 bispecific antibody CM355)
Beyond the preview
Go deeper on Chengdu Kangnuoxing Biopharmaceutical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chengdu Kangnuoxing Biopharmaceutical Technology.